Expression of CD34 on CD19+ Blood Cells in Myeloma
| MoAb . | Epitope . | % of B Cells Expressing CD34 (no. of donors) . | |
|---|---|---|---|
| . | . | MM (10) . | Normal (5) . |
| HPCA-1 | I | 55 ± 5 | 2.6 ± 0.7 |
| Immu-133 | I | 49 ± 5 | 0.8 ± 0.3 |
| Immu-409 | I | 52 ± 6 | 1.6 ± 0.8 |
| 14G3 | I | 44 ± 7 | 1.2 ± 0.4 |
| 43A1 | II | 54 ± 6 | 0.6 ± 0.2 |
| MD34.3 | II | 44 ± 6 | 1.0 ± 0.8 |
| MD34.1 | II | 37 ± 6 | 1.2 ± 0.5 |
| MD34.2 | II | 46 ± 6 | 1.0 ± 0.3 |
| 4A1 | II | 30 ± 7 | 1.6 ± 0.4 |
| 9044 | II | 20 ± 4 | 1.4 ± 0.5 |
| 9049 | II | 32 ± 6 | 1.2 ± 0.4 |
| 581 | III | 48 ± 7 | 1.0 ± 0.5 |
| 570 | III | 55 ± 6 | 4.8 ± 1.5 |
| 553 | III | 48 ± 7 | 1.0 ± 0.3 |
| 563 | III | 51 ± 6 | 1.0 ± 0.8 |
| CD34-9F2 | III | 56 ± 6 | 1.2 ± 0.5 |
| HPCA-2 | III | 50 ± 6 | 2.2 ± 0.7 |
| MoAb . | Epitope . | % of B Cells Expressing CD34 (no. of donors) . | |
|---|---|---|---|
| . | . | MM (10) . | Normal (5) . |
| HPCA-1 | I | 55 ± 5 | 2.6 ± 0.7 |
| Immu-133 | I | 49 ± 5 | 0.8 ± 0.3 |
| Immu-409 | I | 52 ± 6 | 1.6 ± 0.8 |
| 14G3 | I | 44 ± 7 | 1.2 ± 0.4 |
| 43A1 | II | 54 ± 6 | 0.6 ± 0.2 |
| MD34.3 | II | 44 ± 6 | 1.0 ± 0.8 |
| MD34.1 | II | 37 ± 6 | 1.2 ± 0.5 |
| MD34.2 | II | 46 ± 6 | 1.0 ± 0.3 |
| 4A1 | II | 30 ± 7 | 1.6 ± 0.4 |
| 9044 | II | 20 ± 4 | 1.4 ± 0.5 |
| 9049 | II | 32 ± 6 | 1.2 ± 0.4 |
| 581 | III | 48 ± 7 | 1.0 ± 0.5 |
| 570 | III | 55 ± 6 | 4.8 ± 1.5 |
| 553 | III | 48 ± 7 | 1.0 ± 0.3 |
| 563 | III | 51 ± 6 | 1.0 ± 0.8 |
| CD34-9F2 | III | 56 ± 6 | 1.2 ± 0.5 |
| HPCA-2 | III | 50 ± 6 | 2.2 ± 0.7 |
Epitope I: sensitive to neuraminidase, chymopapain, glycoprotease. Epitope II: resistant to neuraminidase, sensitive to chymopapain, glycoprotease. Epitope III: resistant to neuraminidase, chymopapain, glycoprotease. CD34 (indirect) and CD19 (direct) staining was as described in the legend to Table 1. Values represent the mean ± SE; positive staining was that exceeding the isotype-matched control for each MoAb on identically gated CD19+ B cells.